Goldman Sachs Upgrades Mindray Medical (MR) to Buy on Recent Underperformance
Tweet Send to a FriendGet Alerts MR Hot Sheet
Price: $41.48 +0.29%
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade MR Now!
Goldman Sachs upgraded Mindray Medical (NYSE: MR) from Neutral to Buy with a price target of $39.60.
The firm comments, "We upgrade Mindray to Buy (from Neutral) after its recent underperformance (-3% vs. 12% sector average since September 24) and improving risk/reward, driven by 1) strong China and emerging markets sales growth (2013E: 20% vs. 25% in 9M12); 2) margin improvement due to higher IVD reagent sales (50% of total IVD sales by end 2013 vs. 37.4% in 3Q12); and 3) our belief that market concerns on its US earnings weakness are overdone. Our new 12-month Director’s Cut-based target price implies 18% upside potential and we see current valuation as a good entry point."
For an analyst ratings summary and ratings history on Mindray Medical click here. For more ratings news on Mindray Medical click here.
Shares of Mindray Medical closed at $33.72 yesterday, with a 52 week range of $26.17-$36.36.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "We upgrade Mindray to Buy (from Neutral) after its recent underperformance (-3% vs. 12% sector average since September 24) and improving risk/reward, driven by 1) strong China and emerging markets sales growth (2013E: 20% vs. 25% in 9M12); 2) margin improvement due to higher IVD reagent sales (50% of total IVD sales by end 2013 vs. 37.4% in 3Q12); and 3) our belief that market concerns on its US earnings weakness are overdone. Our new 12-month Director’s Cut-based target price implies 18% upside potential and we see current valuation as a good entry point."
For an analyst ratings summary and ratings history on Mindray Medical click here. For more ratings news on Mindray Medical click here.
Shares of Mindray Medical closed at $33.72 yesterday, with a 52 week range of $26.17-$36.36.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- Macquarie Upgrades IntercontinentalExchange (ICE) to Outperform
- UPDATE: Intuit, Inc. (INTU) Tops Q3 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
UpgradesRelated Entities
Goldman Sachs, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
